{
    "clinical_study": {
        "@rank": "8054", 
        "arm_group": {
            "arm_group_label": "131I-rituximab", 
            "arm_group_type": "Experimental", 
            "description": "131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles"
        }, 
        "brief_summary": {
            "textblock": "Marginal zone B-cell lymphoma (MZL) is a lymphoma originated from B-cell in lymph node with\n      variable differentiation status, which is distributed to a variety of organs.\n\n      A high response rate and long term survival is possible through surgery or radiation therapy\n      alone in the case of limited disease. However frequent relapse and progression is observed\n      despite of long term survival. The treatment after relapse has not been established yet.\n\n      So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or\n      relapsed patients with MZL."
        }, 
        "brief_title": "131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed or Refractory Marginal Zone B-cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, B-Cell, Marginal Zone"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed marginal zone B-cell lymphoma\n\n          -  relapsed or refractory patients after treatment including chemotherapy, radiation\n             therapy, and surgery\n\n          -  Eastern Cooperative Oncology Group performance status \u2264 2\n\n          -  age\u2265 20 years\n\n          -  More than one measurable lesion (More than 2cm sized lesion in conventional CT scan,\n             More than 1cm sized lesion in spiral CT or contrast-enhanced PET/CT )\n\n          -  Adequate renal function (serum creatinine \u2264 2.0 mg/dl  or Ccr \u2265 60 ml/min)\n\n          -  Adequate hepatic function (serum bilirubin \u2264 2.0 mg/dl , AST/ALT \u2264 3 upper normal\n             limit)\n\n          -  Adequate bone marrow reservoir (ANC \u22651,500/\u3395, platelet count\u2265 75,000/\u3395)\n\n          -  patient who agree the purpose and intention of this clinical trial\n\n        Exclusion Criteria:\n\n          -  recent (<5 years) history of other malignancy or unrecovered from the disease\n             (appropriately treated skin cancer and uterine cervix carcinoma in situ are excluded)\n\n          -  hemodynamically unstable due to the recent (<12 months) history of severe heart\n             disease such as myocardial infarction\n\n          -  acute complications of severe lung or metabolic disease\n\n          -  Combined severe neurological or psychiatric disease\n\n          -  Unrecovered from infection or other medical disease\n\n          -  Recent (<30 days) history of enrollment of other clinical trial\n\n          -  Pregnant or breast-feeding woman\n\n          -  women of childbearing potential and men not employing adequate contraception at least\n             for 1 year\n\n          -  Previous history drug allergy to the content of 131I-rituximab\n\n          -  Infection(sepsis, pneumonia, viral infection, etc) (inactivated hepatitis B carrier\n             can be enrolled)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678404", 
            "org_study_id": "MZL 131I-rituximab RIT"
        }, 
        "intervention": {
            "arm_group_label": "131I-rituximab", 
            "intervention_name": "131I-rituximab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 4, 2012", 
        "location": {
            "contact": {
                "last_name": "Hye Jin Kang, M.D."
            }, 
            "contact_backup": {
                "last_name": "Dong-Yeop Shin, M.D."
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "139-706"
                }, 
                "name": "Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences"
            }, 
            "investigator": [
                {
                    "last_name": "Hye Jin Kang, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Sung Hyun Yang, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Im Il Na, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hyo-Rak Lee, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dong-Yeop Shin, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sang Moo Lim, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Change Woon Choi, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Byung Il Kim, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ilhan Lim, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Seung-Sook Lee, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma", 
        "overall_contact": {
            "email": "mdhyejin@gmail.com", 
            "last_name": "Hye Jin kang, M.D.", 
            "phone": "+82-2-970-1289"
        }, 
        "overall_contact_backup": {
            "email": "baramg@hanmail.net", 
            "last_name": "Dong-Yeop Shin, M.D.", 
            "phone": "+82-2-970-1246"
        }, 
        "overall_official": {
            "affiliation": "Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences", 
            "last_name": "Hye Jin Kang, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "International Working Group Response criteria", 
            "measure": "Overall response rate", 
            "safety_issue": "No", 
            "time_frame": "up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678404"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response duration", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "description": "grading the adverse events using CTCAE version 4.03", 
                "measure": "Number of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 5 years"
            }
        ], 
        "source": "Korea Cancer Center Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea Cancer Center Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}